That's the company's aim.
However, the counterparty is not obliged to offer an amount equal to sunk development costs. Given we've a had a number of years to attract an offer on 1102, I say there is low likelihood of an $30-40M upfront.
On 1103, I reckon $5M upfront pre-higher dosing study or $10M upfront post-higher dosing study.
Ann: Company Update, page-107
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.9¢ |
Change
-0.001(1.25%) |
Mkt cap ! $83.73M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 7.9¢ | $153.8K | 1.914M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 927041 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 218878 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |